The ithree institute occupies state-of-the-art laboratories in central Sydney, including facilities for pathogen culture. The institute has particular expertise in molecular and cell biology, microbial imaging, genomics, next gen sequencing, bioinformatics, protein chemistry, and vaccine technology.
Our scientists are at the forefront of ongoing development of cutting-edge imaging technologies and have a world-leading facility (Microbial Imaging Facility) that houses a 1.5m AUD super resolution DeltaVision OMX microscope, which was the first of its kind to be delivered to the Southern Hemisphere.
ithree researchers also have access to the UTS Data Arena - a large cylindrical screen that has six 3D-stereo video projectors making it possible for full immersion in microscopy data.
Alongside investment in imaging, UTS has made a substantial commitment to a dedicated proteomics suite that includes leading-edge mass spectrometry machines for high resolution mapping of proteins and other components on the surface of infectious organisms.
Our ability to generate knowledge and develop new tools and treatments will help to reduce morbidity and mortality caused by infectious diseases.
Researchers use these facilities to track pathogens as they invade human and animal cells and explore the mechanisms by which organisms become pathogenic. These studies enable ithree scientists to make fundamental discoveries to identify new targets for the development of drugs, vaccines and diagnostics.
The past decades have seen an explosion in genomic knowledge that is also providing new insights into pathogenic behaviour and microbial evolution. The molecular processes of pathogenicity, including the transfer of genes, are particularly important in understanding how antibiotic resistance is spread.
The institute has invested in next generation DNA sequencing and world-leading microbial genomic bioinformatics as well as array technologies. ithree is a research node of the Ramaciotti genomics institute and it has established links to high throughput genome sequencing facilities in the UK and China, enabling acceleration of research discoveries in line with rapidly advancing technologies.